On Granting Connecticut ND Prescription Rights for 2026 Onward

here, an overview in quite polite language, of: NDs diagnostic and therapeutic adventures of concern, a risk stratification of such concerning activities, an overview of their scope expansion ask for 2026 and beyond, and thoughts on likely deviant usage of what they'd be granted with that scope expansion:

001. first, here's a little bit from the forthcoming Episode 017 script as a formal academic-style write-up, derived from the 2026 CT ND Practices Data set. It particularly looks at the quite abundant aspect of 'expansion and extension in the name of $$$$$' that occurs via those practices' own language, diagnostically and therapeutically:

"[Titled] Diagnostic Expansion and Therapeutic Boundary Stretching in Connecticut Naturopathic Practice.

Abstract

This analysis examines laboratory testing and therapeutic modalities promoted within Connecticut naturopathic clinical materials.

Findings demonstrate a recurring pattern of:

(1) diagnostic expansion through non-validated laboratory panels,

(2) therapeutic boundary extension of legitimate medical technologies beyond approved indications,

and (3) integration of commercially incentivized service models.

These practices raise concerns across public health, ethics, commerce, and scientific integrity domains.

Introduction

Licensed naturopathic physicians in Connecticut operate under a statutory scope that permits laboratory testing and various therapeutic modalities.

However, clinical materials reveal frequent reliance on specialty laboratory panels (e.g., IgG food sensitivity testing, organic acid testing, methylation panels) and non-standard infectious disease diagnostics.

Concurrently, therapies such as homeopathy, low-dose immunotherapy, craniosacral therapy, IV nutrient infusions, hyperbaric oxygen therapy (HBOT), and 'detoxification' regimens are promoted for chronic, medically ambiguous conditions.

Methods

Documents were analyzed for:

• Diagnostic tools outside mainstream consensus guidelines.

• Therapies with weak, refuted, or extrapolated evidence bases.

• Stated clinical indications.

• Implied commercial structure.

Results

Diagnostic Practices

Non-validated laboratory modalities are commonly used to:

• Diagnose 'chronic Lyme disease'

• Identify food sensitivities via IgG panels

• Assess 'adrenal fatigue'

• Detect methylation abnormalities (MTHFR polymorphisms)

• Quantify neurotransmitter imbalances via urine testing

These [diagnostic] practices deviate from consensus recommendations issued by specialty medical societies (infectious disease, allergy/immunology, endocrinology, psychiatry).

Therapeutic Practices

Modalities include:

• Homeopathy (biologically implausible under established pharmacology) 

• Low Dose Immunotherapy (LDI/LDA) 

• Supportive Oligonucleotide Therapy (SOT) for Lyme 

• IV vitamin infusions for non-deficiency states 

• HBOT for chronic Lyme / fatigue 

• Craniosacral therapy 

• Detoxification protocols

Several therapies represent extrapolation beyond FDA-approved or evidence-supported indications.

Discussion

The pattern reflects:

1.    Diagnostic expansion in conditions characterized by clinical uncertainty.

2.    Commercial bundling of laboratory testing and supplement regimens.

3.    Blurring of experimental and established therapeutic categories.

4.    Reinforcement of disease identity through repeated monitoring.

Conclusion

The analyzed materials reveal a parallel diagnostic and therapeutic ecosystem operating adjacent to mainstream standards of care.

This ecosystem presents regulatory, ethical, and public health challenges that merit structured oversight review."

Note: Man, that's some polite language in terms of critique!  Imagine if someone grossly misrepresents why they are doing what they are doing, and overall what they are doing -- based upon what rigorous standards that hew to evidence demand, aka "a high level of scrutiny that strictly follows factual proof" -- but pretends it is justified and legitimate because they are [cough] experts offering an equal or better choice. And it is life and limb kind of stuff! Then, a critique's language approach used is, quite politely, to call it 'expansion, extension, deviation, extrapolation.' How euphemistic. 

002. well, let's not be so polite through qualitative representation, and bring up a risk stratification scoring model for CT NDs' "interventions" by way of that source data, also from the future Episode 017 script:

002.a. the scales [the higher, the worse]:

"Scoring Domains (0–3 scale each):

• Evidence Deficit 

• Biological Implausibility

• Patient Harm Risk

• Delay-of-Care Risk

• Commercial Conflict Intensity

Aggregate Risk Categories:

• 0–4 = Low

• 5–8 = Moderate

• 9–12 = High

• 13–15 = Severe Regulatory Concern."

 002.b. scores:

Intervention	Evidence Deficit	Implausibility	Harm Risk	Delay Risk	Commercial Intensity	Total	Risk Level
Homeopathy	3	3	1	3	2	12	High
SOT for Lyme	3	2	2	3	3	13	Severe
IgG Food Panels	3	1	2	2	3	11	High
Adrenal Fatigue Testing	3	2	1	2	3	11	High
IV Vitamin Therapy (non-deficiency)	2	1	2	2	3	10	High
HBOT (chronic Lyme)	2	1	2	2	3	10	High
Craniosacral Therapy	3	2	1	2	2	10	High
Organic Acid Testing	3	1	1	2	3	10	High
Acupuncture (systemic disease claims)	2	1	1	2	2	8	Moderate

Note: So, the higher the evidence deficit, implausibility, harm risk, delay risk [delay of real diagnostics and therapeutics], commercial intensity [money, money, money] then the greater overall risk of the intervention [whether diagnostic or therapeutic].  What's not shown above is the serious conditions that roughly are the patients' complaint / situation.  But what's happening, as "a parallel diagnostic and therapeutic ecosystem" -- essentially risk -- occurs without any statutory requirements for MD / DO oversight or co-treatment.  The asks section below will show that NDs in CT are seeking even more isolation from such by gaining prescriptive rights towards their ultimate goal of a statutory declaration of 'primary care provider'.

003. a summary of what NDs want via Perplexity from the task "What kind of prescription rights are naturopaths asking for in Connecticut as an extension of their scope of practice?":

"Connecticut naturopathic physicians are asking for broad, independent prescriptive authority that would let them prescribe, dispense, and administer a wide range of prescription drugs and related substances, not just a narrow list like vitamin B12.

Core prescriptive rights they’re seeking

From the 2024–2025 Department of Public Health scope-of-practice review application submitted by the Connecticut Naturopathic Physicians Association (CNPA), the main requests are:

• The ability to independently prescribe pharmaceuticals (i.e., prescription medications generally, not limited to a short formulary).
• The ability to independently dispense pharmaceuticals directly to patients.
• The ability to independently administer pharmaceuticals, natural substances, and nutraceuticals by multiple routes, including auricular, buccal, inhaled, intranasal, intramuscular, intravenous, and others.

These requested changes would be a significant expansion from current Connecticut law, under which naturopaths cannot prescribe prescription medications at all and instead must refer patients back to an MD, APRN, PA, etc., for any drug prescribing.

How this shows up in recent legislation

Recent and pending bills capture different “slices” of this broader ask:

Item	What it does	Relation to broader ask
SB 177 (2024)	“An Act Authorizing Naturopathic Physicians To Prescribe Medication.” It’s a general prescriptive-authority bill without spelling out a narrow list in the short summary.	Tracks the core request for general prescribing authority over medications.
SB 1325 (2025)	“An Act Permitting Naturopathic Physicians To Prescribe And Administer Vitamin B12.”	Much narrower; a single substance and route, often seen as an incremental or compromise measure rather than the full CNPA request.
SB 1069 (2025 session tracking)	“AN ACT PERMITTING NATUROPATHIC PHYSICIANS TO PRESCRIBE MEDICATION.”	Another vehicle for general medication-prescribing authority, aligned with the broad scope expansion sought in the DPH review.

So at the policy level you have two tracks: (1) the profession’s formal DPH scope-of-practice request, which is broad (prescribe, dispense, administer by multiple routes), and (2) individual bills that either mirror that broad aim (“prescribe medication”) or carve out narrow pieces like vitamin B12.

Other scope-related asks around prescribing

In addition to the specific prescriptive rights, CNPA's scope-of-practice submission also asks for related changes that would position naturopaths more like primary care providers in statute, such as:

• Inclusion of naturopathic physicians in future legislative considerations affecting primary care-type providers.
• Removal of statutory language they view as obstacles to providing “comprehensive care in one location,” including the combination of diagnosis, lab ordering, and prescribing in a single office.

These are framed as supporting the main prescriptive goal by making it easier for naturopaths to manage both diagnosis and medication management within their own scope of practice."

004. what the science says about what NDs are doing diagnostically and therapeutically of concern via "survey tables":

004.a. the task to Perplexity:

"Can you elaborate on Connecticut naturopaths' 'non‑validated diagnostic and therapeutic practices' with a survey table: one for diagnostics and their scientific refutation, and one for therapeutics and their scientific refutation?"

004.b. the answer: 

"Connecticut naturopaths commonly employ diagnostic tests and therapies that diverge from mainstream medical consensus, often relying on non-standard or refuted methods as highlighted in the attached PDF analysis.

Non-Validated Diagnostics

Diagnostic practice	Description	Scientific refutation or critique
IgG food sensitivity testing	Blood tests measuring IgG antibodies to foods, used to identify "sensitivities" causing chronic symptoms.	Lacks clinical utility; major allergy societies (e.g., AAAAI, ACAAI) state IgG levels reflect exposure, not allergy or intolerance; no causal link to symptoms proven in controlled trials.
Organic acid testing (OAT)	Urine analysis for metabolic byproducts to assess gut dysbiosis, neurotransmitter issues, or detoxification capacity.	Not validated for clinical diagnosis; American Academy of Pediatrics and other bodies reject for routine use due to poor specificity / sensitivity and overlap with normal variation.
"Chronic Lyme disease" testing	Non-standard panels (e.g., beyond CDC two-tier serology) for persistent infection post-treatment.	Infectious Diseases Society of America (IDSA) guidelines refute; most positive results represent false positives or past infection; no reliable test for "chronic Lyme."
Adrenal fatigue assessment	Salivary cortisol patterns or DHEA levels to diagnose "subclinical" adrenal insufficiency.	Endocrine Society declares "adrenal fatigue" unproven; cortisol tests unreliable outside clinical deficiency states; symptoms nonspecific and better explained by other causes.
Methylation panels (e.g., MTHFR polymorphisms)	Genetic or functional tests for methylation defects linked to fatigue, mood disorders.	American College of Medical Genetics: MTHFR variants common (up to 40% population), not causal for most symptoms; treatment (e.g., folate megadosing) lacks evidence.
Urine neurotransmitter testing	Quantifies dopamine, serotonin, etc., in urine to guide supplementation for imbalances.	Psychiatry and neurology consensus: urine levels do not reflect brain function; poor correlation with central nervous system activity; no validated therapeutic application.

Non-Validated Therapeutics

Therapeutic practice	Description	Scientific refutation or critique
Homeopathy	Ultra-dilute remedies claimed to stimulate healing via "like cures like."	Biologically implausible; meta-analyses (e.g., Lancet 2005, NHMRC 2015) show effects indistinguishable from placebo; contradicts pharmacology principles.
Low-dose immunotherapy (LDI/LDA)	Subcutaneous microdoses of allergens/antigens for allergies, autoimmunity, chronic illness.	No rigorous RCTs support efficacy; AAAAI warns of risks without benefits; deviates from standard immunotherapy dosing validated for IgE-mediated allergy.
Supportive oligonucleotide therapy (SOT) for Lyme	Peptide or nucleic acid sequences targeting supposed persistent Lyme pathogens.	Lacks FDA approval or clinical trial data; IDSA rejects as unproven for "chronic Lyme"; potential for immune overstimulation without proven pathogen clearance.
IV nutrient infusions for non-deficiency states	High-dose vitamins/minerals IV for fatigue, infections, detoxification.	No evidence for routine use beyond deficiency; risks include vein damage, infection; American College of Physicians: unsupported for chronic conditions.
Hyperbaric oxygen therapy (HBOT) for chronic Lyme/fatigue	Off-label HBOT for persistent symptoms, not wound healing.	FDA restricts HBOT to 13 indications; Undersea and Hyperbaric Medical Society: no data for Lyme or fatigue; risks include barotrauma, oxygen toxicity.
Craniosacral therapy	Gentle skull/sacral manipulation for pain, neurological issues.	No measurable cranial bone motion exists; systematic reviews (e.g., Cochrane) find no benefit beyond placebo for any condition.
Detoxification protocols	Colonics, chelation, saunas for "toxin" removal in chronic illness.	No evidence toxins accumulate as claimed; NIH and gastroenterology societies: unnecessary/risky for healthy individuals; may disrupt microbiome.

"

005. in light of all that, predicting the future:

005.a. then this task was requested:

"With the survey tables in mind from the second query, what seems the likelihood -- if naturopaths are granted what they want per the first query -- that Connecticut naturopaths will be as deviant from standard of care -- or to be more polite 'extended' or 'stretched' -- in terms of how they will use what they would be allowed to prescribe since a pattern already exists of diagnostic and therapeutic 'extension or stretching'?"

005.b. the answer:

"Given the existing pattern, the likelihood that Connecticut naturopaths would use new prescriptive powers in an equally “stretched” or non‑standard way is high.

Why the likelihood is high

1.       Established pattern of non‑standard diagnostics and treatment choices

o   Naturopaths in Connecticut already rely on non‑validated diagnostic tools (IgG food panels, non‑standard Lyme testing, adrenal fatigue labs, urine neurotransmitters, methylation panels) in ways that depart from consensus guidelines in allergy, infectious disease, endocrinology, and psychiatry.

o   They similarly “stretch” legitimate modalities (IV infusions, HBOT) far beyond evidence‑supported indications, especially for chronic Lyme, fatigue, and other medically ambiguous conditions.

o   This shows a stable practice culture that favors extension of tools beyond standard-of-care boundaries rather than tight adherence to consensus standards.

2.       Direct evidence of a parallel care ecosystem

o   The PDF characterizes current naturopathic practice as a parallel diagnostic and therapeutic ecosystem, operating adjacent to mainstream standards of care, with blurred lines between experimental and established therapies.

o   Within this ecosystem, “stretching” is not an exception but a core organizing principle: diagnostic categories (chronic Lyme, adrenal fatigue) are widened; monitoring is repeated; commercial bundles of labs, supplements, and adjunctive procedures (IV, HBOT, saunas) are marketed as comprehensive care.

o   Adding prescriptive authority to this ecosystem is far more likely to be assimilated into the same pattern than to transform the practice culture toward conventional restraint.

3.       Scope request explicitly integrates prescribing into existing one‑stop model

o   The CNPA scope‑of‑practice request is framed around “comprehensive care in one location,” specifically combining diagnosis, lab ordering, and prescribing/administration in the naturopathic office.

o   They seek not only prescribing but also dispensing and administration (including IV, IM, inhaled, intranasal routes) and positioning as primary‑care‑type providers in statute.

o   That design embeds prescribing into the same business and conceptual framework that already drives use of non‑validated diagnostics and boundary‑stretched therapeutics, making similar “extension” of drug use structurally likely.

4.       External observers anticipate non‑standard prescribing if authority is granted

o   The AMA’s impact statement on the CNPA scope review warns that granting broad prescriptive authority to naturopaths—without the usual limitations on controlled substances that most states impose—poses a “serious threat” to patient safety, precisely because of misinformed or non‑evidence‑based prescribing.

o   Testimony and policy analyses emphasize that Connecticut would be an outlier if it granted such expansive authority, and highlight existing naturopathic reliance on unproven chronic Lyme protocols, IV therapies, and other non‑standard interventions as a warning signal for future prescribing behavior.

o   In other words, independent medical and policy actors are already inferring a high probability that drug use would mirror the current “stretching” seen with non‑drug modalities.

5.       Concrete examples of “stretching” that would naturally translate to drugs

o   Current Connecticut naturopathic marketing for chronic Lyme and complex chronic illness showcases aggressive use of HBOT, IV nutrient infusions, and adjunct therapies as primary tools, with strong causal claims that go beyond current evidence.

o   Given this model, broad prescriptive authority would simply add antibiotics, antivirals, psychotropics, hormones, and other agents as additional levers within the same extended protocols, especially for patients already labeled via non‑validated diagnostic schemes.

o   For example, the same practice logic that leads to IV vitamins and HBOT for chronic Lyme would almost certainly favor prolonged or combination antibiotic regimens, “neurotransmitter‑balancing” psychotropics based on urine tests, or hormone manipulation for adrenal fatigue, all in ways that deviate from IDSA, psychiatry, and endocrinology guidelines.

Overall judgment

Putting these elements together:

• the base rate behavior (current diagnostics and therapies)
• the structure of the requested scope (one‑stop diagnosis + labs + prescribing / administration)
• and independent policy assessments all align.

If naturopaths are granted the broad prescriptive, dispensing, and administration authority they seek, it is very likely that they will use those powers in an 'extended' or 'stretched' manner comparable to how they already use non‑validated diagnostics and non‑drug modalities.

A conservative characterization would be: the probability is closer to 'expected behavior' than to 'edge case'—i.e., deviation from standard of care in prescribing would be normal and predictable, not rare or accidental, given the existing pattern."

Note: The current partnership between the State of Connecticut and the Connecticut NDs is one of deference, not oversight. Everything entailed above is allowed under a supposed oversight structure that itself labels naturopaths' activities, because they are naturopaths, "the science, art, and practice". The law does not hold naturopathy to scientific standards, or scientific review. It states that because it is what naturopaths are doing, it is science by legal fiat. CUTPA, consumer rights, patient rights, student rights be damned. And you will see the State of Connecticut aid in their expansion, as they always do, and allow their, to be polite "expansion, extension, deviation, extrapolation" -- furthering a regressive anti-rigor anti-accountability naturopathic agenda.

006. afterword:

I though this an appropriate quote that was written in the New York Times by Jeneen Interlandi today 2026-02-23 [she's talking about the Federal government, I'm borrowing it towards my State government]:

"discourse on crucial scientific questions and key public health challenges has been stifled [...] trust has been broken between scientists, the nation’s leaders [let's say here Connecticut's governance] -- and the people that both are supposed to serve [...] science, medicine and public health have been hijacked by a cadre of grifters and ideologues and by the politicians in obvious thrall to both."

Not only there, there [Federally imposed]...but here, here [state conceived and maintained].